Michigan Pharmacy and Therapeutics Committee  
March 14, 2017 6:00 PM  
Kellogg Center, East Lansing, Michigan

Agenda

I. Introductions
II. Conflict of Interest Statement
III. Approval of the Agenda
IV. Approval of Minutes of December, 2016 Meeting
V. P & T Business
   A. Policy updates – Rita Subhedar
   B. Legislative updates

VI. Old Business
   A. Hepatitis C Update
   B. Vopac MDS
   C. Jardiance

New Drugs
1. Bromsite (bromfenac) ophthalmic drops - [PDL class: Ophthalmics: NSAIDS; non-preferred]
2. Byvalson (nebivolol/valsartan)- [PDL class: Antihypertensive Combinations: ARBs; non-preferred]
3. DermacinRx Therazole Pak (clotrimazole/betamethasone/zinc) - [PDL class: Antifungals: Topical; non-preferred]
4. Gonitro (nitroglycerin) sublingual powder - [Not a PDL Class; Add to MPPL with PA]
5. Invokamet XR (canagliflozin/metformin) tablets - [PDL class: Oral hypoglycemics: Combinations; non-preferred]
6. Micort-HC (hydrocortisone) cream – [PDL class: Topical Steroids: Low Potency; non-preferred]
7. Otovel (ciprofloxacin/fluocinolone) otic drops – [PDL class: Otic Quinolones; non-preferred]
8. Qbrelis (lisinopril) oral solutions – [PDL class: ACE Inhibitors; non-preferred]
9. Yosprala DR (aspirin/omeprazole) tablets – [PDL class: Platelet Aggregation Inhibitors; non-preferred]
10. Zurampic (lesinurad) tablets - [Not a PDL Class; Add to MPPL with PA]
Review of Preferred Drug List Classes

A. Ophthalmics:
   1. Glaucoma: Alpha-2 Adrenergics
      a. No change to the current classification of drug products
   2. Glaucoma: Beta Blockers
      a. Move betaxolol (generic for Betoptic) to non-preferred
   3. Glaucoma: Prostaglandin Inhibitors
      a. No change to the current classification of drug products
   4. Glaucoma: Carbonic Anhydrase Inhibitors
      a. No change to the current classification of drug products
   5. Glaucoma: Combination Alpha-2 Adrenergic/Beta Blocker
      a. No change to the current classification of drug products
   6. Ophthalmic Antihistamines
      a. Move Patanol (olapatadine) to non-preferred
   7. Ophthalmic Mast Cell Stabilizers
      a. No change to the current classification of drug products
   8. Ophthalmic NSAIDs
      a. No change to the current classification of drug products

B. Cardiac:
   1. ACE Inhibitors
      a. No change to the current classification of drug products
   2. Alpha Adrenergic Agents
      a. No change to the current classification of drug products
      b. Remove reserpine from the PDL.
   3. Antihypertensive Combinations: ACEI-CCB
      a. No change to the current classification of drug products
   4. Antihypertensive Combinations: ARB-CCB
      a. No change to the current classification of drug products
   5. Angiotensin Receptor Antagonists (ARBs)
      a. Move Benicar (olmesartan) and Benicar HCT (olmesartan/HCTZ) to non-preferred
      b. Remove Entresto from the ARB subclass and create new cardiovascular subclass for
         Entresto - Angiotensin II-Receptor Neprilysin Inhibitors (ARNIs).
   6. Direct Renin Inhibitors
      a. No change to the current classification of drug products
   7. Beta Blockers
      a. Move nadolol/bendromethazide (generic for Corzide) to non-preferred
      b. Move propranolol/HCT (generic for Inderide) to non-preferred
   8. Calcium Channel Blockers-Dihydropyridine
      a. No change to the current classification of drug products
   9. Calcium Channel Blockers-Non-Dihydropyridine
      a. No change to the current classification of drug products
10. Lipotropics - Antihypertensive Combinations  
a. No change to the current classification of drug products

11. Lipotropics - Non-Statins: Fibric Acid Derivatives  
a. Move fenofibrate (generic for Lofibra) capsules only to non-preferred

12. Lipotropics - Non-Statins: Bile Acid Sequestrants  
a. Move colestipol (generic for Colestid) granules only to non-preferred

13. Lipotropics: Statins  
a. Move Crestor to non-preferred
b. Move rosuvastatin to preferred
c. Move pravastatin to preferred

14. Lipotropics: Niacin Derivatives  
a. No change to the current classification of drug products

15. Lipotropics: Other  
a. No change to the current classification of drug products

16. Lipotropics: PCSK9 Inhibitors  
a. No change to the current classification of drug products

17. Anticoagulants  
a. Move Eliquis (apixaban) to preferred
b. Move Arixtra (fondaparinux) to non-preferred
c. Move Fragmin (dalteparin) vials only to non-preferred

18. Antiplatelets  
a. Move Brilinta (ticagrelor) to preferred

19. Pulmonary Arterial Hypertension (PAH) Agents  
a. No change to the current classification of drug products

Public Comments: Comments are limited to 5 minutes, regardless of the number of medications to be presented. If there are more than 12 presenters, the time allotment will be prorated to accommodate the number of requests within a one hour timeframe.

1. Tom Constance, PharmD, Gilead Sciences, re. PAH
2. Rick Dettloff, PharmD, Pfizer, Inc., re. Eucrisa
3. Shefali Mihelich, Boehringer Ingelheim Pharmaceuticals, Inc., re. Stiolto Respimat and GOLD guidelines update
4. Kunal Ramani, PharmD, Actelion Pharmaceuticals, re. Uptravi (selexipag) and Opsumit (macitentan)
5. Ndidi Yaucher, PharmD, Novartis Pharmaceutical Corps., re. Tobi Podhaler
6. Zev Winicur, PhD, United Therapeutics, re. Orenitram ER Tablets

Next Meeting: Tuesday, June 14, 2017  
Location: Kellogg Center  
Drug Classes: Anti-Infectives  
Asthma/COPD/Allergy